L-Ascorbic acid can abrogate SVCT-2-dependent cetuximab resistance mediated by mutant KRAS in human colon cancer cells

Colorectal cancer statistics, 2014

Rebecca L. Siegel, Carol DeSantis, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2014 · 2.6K citations · Full text

Medicine, Oncology, Cancer Epidemiology +16

<i>KRAS</i> Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer

Astrid Lièvre, Jean‐Baptiste Bachet, Delphine Le Corre et al. · Cancer Research · 2006 · 2.2K citations

Medicine, Oncology, Pharmacology +17

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

Sandra Misale, Rona Yaeger, Sebastijan Hobor et al. · Nature · 2012 · 1.9K citations · Full text

Medicine, Molecular Genetics, Oncology +16

Mitogen-Activated Protein Kinases and Reactive Oxygen Species: How Can ROS Activate MAPK Pathways?

Yong Son, Yong-Kwan Cheong, Nam‐Ho Kim et al. · Journal of Signal Transduction · 2011 · 1.2K citations · Full text

Life Sciences, Cell Biology, Molecular Biology +16

Vitamin C selectively kills <i>KRAS</i> and <i>BRAF</i> mutant colorectal cancer cells by targeting GAPDH

Jihye Yun, Edouard Mullarky, Changyuan Lu et al. · Science · 2015 · 910 citations

Medicine, Cancer Biology, Oncology +14